A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)
| Autor: | Groen, H.J.M. *, Socinski, M.A., Grossi, F., Juhasz, E., Gridelli, C., Baas, P., Butts, C.A., Chmielowska, E., Usari, T., Selaru, P., Harmon, C., Williams, J.A., Gao, F., Tye, L., Chao, R.C., Blumenschein, G.R., Jr |
|---|---|
| Zdroj: | In Annals of Oncology September 2013 24(9):2382-2389 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|